Alembic Gets USFDA Nod for Generic Anti-Epileptic Drug
By Rediff Money Desk, New Delhi Dec 20, 2024 16:30
Alembic Pharmaceuticals receives USFDA approval for generic Divalproex Sodium delayed-release capsules, a treatment for epilepsy. The drug is therapeutically equivalent to Depakote Sprinkle capsules.

New Delhi, Dec 20 (PTI) Alembic Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic Divalproex Sodium delayed-release capsules, used in the treatment of epilepsy.
The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Divalproex Sodium delayed-release capsules of strength 125 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Depakote Sprinkle capsules, 125 mg of AbbVie Inc, it added.
Divalproex Sodium is an anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures, it added.
Citing IQVIA data, the company said Divalproex Sodium delayed-release capsules 125 mg have an estimated market size of USD 61.1 million for 12 months ended September 2024.
The approval granted by the US Food & Drug Administration (USFDA) for the abbreviated new drug application (ANDA) of Divalproex Sodium delayed-release capsules of strength 125 mg, Alembic Pharmaceuticals said in a regulatory filing.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug product (RLD), Depakote Sprinkle capsules, 125 mg of AbbVie Inc, it added.
Divalproex Sodium is an anti-epileptic drug indicated for monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures, it added.
Citing IQVIA data, the company said Divalproex Sodium delayed-release capsules 125 mg have an estimated market size of USD 61.1 million for 12 months ended September 2024.
Source: PTI
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone Idea L
- 9.47 (+ 2.05)
- 61048233
- Thinkink Picturez
- 0.45 ( 0.00)
- 22664084
- G G Engineering
- 1.22 ( -3.94)
- 18109205
- Srestha Finvest
- 0.69 ( -1.43)
- 12131937
- Hathway Cable & Data
- 14.75 ( -2.12)
- 11583833
MORE NEWS

Prestige Estates Plans Rs 30K Cr Housing Launch...
Prestige Estates to launch Rs 30,000 crore worth of housing projects in Q4 FY25,...

Madhya Pradesh Attracts Rs 1.8 Lakh Cr...
Madhya Pradesh CM Mohan Yadav secured Rs 1.8 lakh crore in investment commitments ahead...

Diriyah Giga Project Attracts Indian Investors
Diriyah, a USD 63 billion Saudi Arabian giga project, sees keen interest from Indian...